Glucagon-like peptide-1 receptor agonists on cardioprotective effects in heart failure
Pang Xuyao
Liu Qianpeng
Gao Man
Zhang Feifei
Abstract：Glucagon-like peptide-1 receptor agonists(GLP-1RAs)have been widely used in the management of type 2 diabetes mellitus(T2DM)and obesity.Numerous clinical trials have confirmed their cardioprotective effects in patients with heart failure(HF).As a representative GLP-1RA,semaglutide has demonstrated benefits in various cardiovascular events in multiple large-scale cardiovascular outcome trials(CVOTs).Therefore,this study systematically summarizes the clinical trial and basic research evidence regarding the cardioprotective mechanisms of semaglutide in heart failure,aiming to provide a ref-erence for exploring new therapeutic approaches in patients with heart failure.
Keywords：Heart FailureGlucagon-like peptide-1 receptor agonistsSemaglutideCardioprotection
Publication Date：2026-02-18
Online Publishing Date：2026-03-18(First online date of this platform, not the publication date of the document)
Pages：5( 238-242 )